Incyte Corp (INCY)

137.77
1.51 1.08
NASDAQ : Health Care
Prev Close 139.28
Open 140.10
Day Low/High 137.69 / 140.94
52 Wk Low/High 55.00 / 133.62
Volume 1.11M
Avg Volume 2.53M
Exchange NASDAQ
Shares Outstanding 203.82M
Market Cap 28.43B
P/E Ratio 258.30
Div & Yield N.A. (N.A)

Latest News

Incyte Corporation Stock Rises on Price Target Increase

Incyte Corporation Stock Rises on Price Target Increase

Incyte Corp. climbed premarket after Credit Suisse raised its price target to $174.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.

Incyte Likely to Incite Further Gains

Incyte Likely to Incite Further Gains

Approach the long side of this great biopharma play on any shallow dip in price, like one or two dollars.

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Big market gains were the result of great companies, CEOs and the people behind them -- not just the Fed, says Jim Cramer.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Incyte's Targeted Therapy And Immuno-oncology Portfolio To Be Featured In 20 Abstracts At The AACR Annual Meeting 2017

Incyte's Targeted Therapy And Immuno-oncology Portfolio To Be Featured In 20 Abstracts At The AACR Annual Meeting 2017

Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research (AACR) annual meeting in Washington, D.

Voices Of MPN Heroes Video

Voices Of MPN Heroes Video

Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURODIS) and other rare disease health organizations and advocates in recognizing Rare...

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Biotech Movers: Cempra Flys High On Phase Three Results

Biotech Movers: Cempra Flys High On Phase Three Results

Other movers include Incyte, Achillion and Inovio.

Incyte Announces Oncology Research Alliance With The Abramson Cancer Center At The University Of Pennsylvania

Incyte Announces Oncology Research Alliance With The Abramson Cancer Center At The University Of Pennsylvania

Incyte Corporation (Nasdaq:INCY) today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania.

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 37 th Annual Health Care Conference on Wednesday,...

Softness in Incyte Should Be Short-Lived, if Our Quants Are Right

Softness in Incyte Should Be Short-Lived, if Our Quants Are Right

A trade at $126 will be a new high for the move up.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRVL, INCY, WHLR Downgrades: BABA, FLO, ITT, TPX Initiations: AUXO Read on to get TheStreet Quant Ratings' detailed report:

Http://www.agenusbio.com

Http://www.agenusbio.com

Incyte Corporation (Nasdaq:INCY) and Agenus Inc. (Nasdaq:AGEN) announced today that the companies have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015.

Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs

Incyte Reports 2016 Fourth-Quarter And Year-End Financial Results, Provides 2017 Financial Guidance And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2016 fourth-quarter and year-end financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are declining Tuesday while European and Asian shares trade mixed ahead of congressional testimony from Federal Reserve Chair Janet Yellen.

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.

Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor

Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-in-class, Small Molecule Arginase Inhibitor

Incyte Corporation (NASDAQ:INCY) and Calithera Biosciences, Inc. (NASDAQ:CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and...

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Merck Cancer Drug Test Sends Incyte Shares Higher

Merck Cancer Drug Test Sends Incyte Shares Higher

The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Biotech Stocks Surge Monday Amid Flurry of Deal Activity

Deals, though, weren't the only mover of share prices.